Articles

Transcriptional landscape of nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich large B-cell lymphoma: tumor microenvironment and checkpoint genes

Research Program Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, Helsinki
Duke University, Durham, North Carolina
Duke University, Durham, North Carolina
Duke University, Durham, North Carolina
Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki
Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki
Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki
Research Program Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki
Data Driven Bioscience, Durham, North Carolina
Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia
Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia
Pathology and Laboratory Medicine Institute at Cleveland Clinic, Cleveland, Ohio
Mayo Clinic, Rochester, Minnesota
Vanderbilt University Medical Center, Nashville, Tennessee
Vanderbilt University Medical Center, Nashville, Tennessee, United States; PathGroup, Nashville, Tennessee
Duke University, Durham, North Carolina
Duke University, Durham, North Carolina
Data Driven Bioscience, Durham, North Carolina
Data Driven Bioscience, Durham, North Carolina
Data Driven Bioscience, Durham, North Carolina
Duke University, Durham, North Carolina
Department of Pathology, Zealand University Hospital, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, Indiana
Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, Indiana
Neogenomics, Fort Myers, Florida
Department of Pathology, Yale University, New Haven, Connecticut
Department of Pathology and Laboratory Medicine, University of Rochester, Rochester, New York
Department of Anatomical Pathology, Singapore General Hospital
Duke University, Durham, North Carolina
Duke University, Durham, North Carolina
University of Hong Kong, Hong Kong
University of Hong Kong, Hong Kong
Stanford University Medical Center, Stanford, California
Massachusetts General Hospital, Boston, Massachusetts
Department of Pathology, University of Miami and Sylvester Comprehensive Cancer Center, Miami, Florida
University of Nebraska, Omaha, Nebraska
Department of Pathology, Weill Cornell Medical College, New York, New York
University of North Carolina, Chapel Hill, North Carolina
Cleveland Clinic Florida, Weston, Florida
University of Illinois, Chicago, Illinois
Robert Wood Johnson Medical School, New Brunswick, New Jersey
Rutgers Cancer Institute, New Brunswick, New Jersey
Pathology Program, Translational Science and Therapeutics Division, Department of Pathology, Fred Hutchinson Cancer Center, Seattle, Washington
Duke University, Durham, North Carolina
Research Program Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, Helsinki
Haematologica Early view Nov 12, 2026 https://doi.org/10.3324/haematol.2026.301728